Nivolumab/pembrolizumab

Nivolumab/pembrolizumab Reactions 1704, p283 - 2 Jun 2018 ALT increased: case report In a study of seven patients, one patient [age and sex not stated] was described who developed ALT rise following treatment with nivolumab and pembrolizumab [routes, dosgaes, durations of treatments to reaction onset not stated]. The patient, who had cancer [unspecified], received treatment with nivolumab and pembrolizumab. The patient also had concurrent HCV infection. Subsequently, the patient developed rise in ALT level (grade II). Therefore, the patient received treatment for HCV infection and consequently the ALT level returned to baseline. Author comment: "Our results indicate that patients with metastatic melanoma and NSCLC can be safely treated with anti-PD1 immunotherapy in the context of HBV/HCV infection. Only one patient demonstrated an ALT rise greater than CTCAE Grade 1 severity". Kothapalli A, et al. Safety and efficacy of anti-PD1 therapy for metastatic melanoma and non-small cell lung cancer in patients with concurrent viral hepatitis. Australasian Journal of Dermatology 59 (Suppl. 1): 79, May 2018. Available from: URL: http://doi.org/10.1111/ajd.17_12815 [abstract] - Australia 803323376 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Nivolumab/pembrolizumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/nivolumab-pembrolizumab-tk5sMKY0nu
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46926-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p283 - 2 Jun 2018 ALT increased: case report In a study of seven patients, one patient [age and sex not stated] was described who developed ALT rise following treatment with nivolumab and pembrolizumab [routes, dosgaes, durations of treatments to reaction onset not stated]. The patient, who had cancer [unspecified], received treatment with nivolumab and pembrolizumab. The patient also had concurrent HCV infection. Subsequently, the patient developed rise in ALT level (grade II). Therefore, the patient received treatment for HCV infection and consequently the ALT level returned to baseline. Author comment: "Our results indicate that patients with metastatic melanoma and NSCLC can be safely treated with anti-PD1 immunotherapy in the context of HBV/HCV infection. Only one patient demonstrated an ALT rise greater than CTCAE Grade 1 severity". Kothapalli A, et al. Safety and efficacy of anti-PD1 therapy for metastatic melanoma and non-small cell lung cancer in patients with concurrent viral hepatitis. Australasian Journal of Dermatology 59 (Suppl. 1): 79, May 2018. Available from: URL: http://doi.org/10.1111/ajd.17_12815 [abstract] - Australia 803323376 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off